Emerging Technologies in Alzheimer’s Diagnosis: From PET Scans to Blood Tests

According to FutureWise analysis, the market for Alzheimer’s Disease Diagnostic is expected to reach US$ 10.86 billion by 2031 at a CAGR of 5.28% over the forecast period of 2023-2031.

Alzheimer's is a profound neurodegenerative disease that begins with subtle memory lapses and gradually deepens into a more challenging experience. Initially, affected individuals may notice slight forgetfulness, but as the disease progresses, it can erode vital social interactions and communication skills. Regrettably, there is currently no cure for Alzheimer's, and the journey it takes is marked by a lengthy preclinical phase leading to a steady decline in cognitive abilities and daily functioning. For many, the haunting symptoms of late-onset Alzheimer's emerge in their mid-60s, while early-onset Alzheimer's is a rare phenomenon, arriving unexpectedly for some between the ages of 30 and 64. Alzheimer's disease stands as the most prevalent form of dementia among older adults, casting a shadow on the lives and loved ones of those it touches.

FutureWise Market Research has published a report that provides an insightful analysis of Alzheimer’s Disease Diagnostic Market trends affecting overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=10644%20&type=requestsample

Alzheimer’s Disease Diagnostic Market Segmentation:

By Product Type
• Brain Imaging
• CFS Test for Alzheimer’s Disease

By Type
• Early-Onset
•Late-Onset
• Familial

By End User
• Hospitals
• Specialty Clinics/ Diagnostic Centers
• Ambulatory Surgical Centers
• Academic & Research Institutes 

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in the Alzheimer’s Disease Diagnostic Market:

• TuaRx
  • Alector LLC
  • Eli Lilly and Company
  •  Treventis Corporation
  • Neuro-Bio Ltd
  • Accera, Inc.
  • Cognition Therapeutics Inc.
  • Johnson Johnson
  • F. Hoffmann-La Roche Ltd
  •  Quanterix
  • Sysmex
  • Novartis AG
  • Allergan PLC
  • C2N Diagnostics
  • Randox Bioscience
  •  GE Healthcare
  • MAGQU CO. LTD.
  • Hitachi

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=10644&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Alzheimer’s Disease Diagnostic Market By Product Type, By Type, By End-Use and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Related market: 
Some of the other related markets that you might be interested in are listed as below:

Alzheimer's Disease Drug Market

Alzheimers Disease Diagnostics and Therapeutics Market

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com

Article source: https://article-realm.com/article/Health-Fitness/72102-Emerging-Technologies-in-Alzheimer-s-Diagnosis-From-PET-Scans-to-Blood-Tests.html